Literature DB >> 30721028

High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.

Padma Kadiyala, Dan Li, Fernando M Nuñez, David Altshuler, Robert Doherty, Rui Kuai, Minzhi Yu, Neha Kamran, Marta Edwards, James J Moon, Pedro R Lowenstein, Maria G Castro, Anna Schwendeman.   

Abstract

Glioblastoma multiforme (GBM) is an aggressive primary brain tumor, for which there is no cure. Treatment effectiveness for GBM has been limited due to tumor heterogeneity, an immunosuppressive tumor microenvironment (TME), and the presence of the blood-brain barrier, which hampers the transport of chemotherapeutic compounds to the central nervous system (CNS). High-density lipoprotein (HDL)-mimicking nanodiscs hold considerable promise to achieve delivery of bioactive compounds into tumors. Herein, we tested the ability of synthetic HDL nanodiscs to deliver chemotherapeutic agents to the GBM microenvironment and elicit tumor regression. To this end, we developed chemo-immunotherapy delivery vehicles based on sHDL nanodiscs loaded with CpG, a Toll-like receptor 9 (TLR9) agonist, together with docetaxel (DTX), a chemotherapeutic agent, for targeting GBM. Our data show that delivery of DTX-sHDL-CpG nanodiscs into the tumor mass elicited tumor regression and antitumor CD8+ T cell responses in the brain TME. We did not observe any overt off-target side effects. Furthermore, the combination of DTX-sHDL-CpG treatment with radiation (IR), which is the standard of care for GBM, resulted in tumor regression and long-term survival in 80% of GBM-bearing animals. Mice remained tumor-free upon tumor cell rechallenge in the contralateral hemisphere, indicating the development of anti-GBM immunological memory. Collectively, these data indicate that sHDL nanodiscs constitute an effective drug delivery platform for the treatment of GBM, resulting in tumor regression, long-term survival, and immunological memory when used in combination with IR. The proposed delivery platform has significant potential for clinical translation.

Entities:  

Keywords:  HDL nanodiscs; chemo-immunotherapy; drug delivery; glioma; local therapy; nanoparticles

Mesh:

Substances:

Year:  2019        PMID: 30721028      PMCID: PMC6484828          DOI: 10.1021/acsnano.8b06842

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  64 in total

Review 1.  HDL: the metabolism, function, and therapeutic importance.

Authors:  Minghan Wang; Michael R Briggs
Journal:  Chem Rev       Date:  2004-01       Impact factor: 60.622

2.  Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents.

Authors:  Jerry D Glickson; Sissel Lund-Katz; Rong Zhou; Hoon Choi; I-Wei Chen; Hui Li; Ian Corbin; Anatoliy V Popov; Weiguo Cao; Liping Song; Chenze Qi; Diane Marotta; David S Nelson; Juan Chen; Britton Chance; Gang Zheng
Journal:  Mol Imaging       Date:  2008 Mar-Apr       Impact factor: 4.488

3.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

4.  The secretion of HMGB1 is required for the migration of maturing dendritic cells.

Authors:  Ingrid E Dumitriu; Marco E Bianchi; Monica Bacci; Angelo A Manfredi; Patrizia Rovere-Querini
Journal:  J Leukoc Biol       Date:  2006-10-11       Impact factor: 4.962

Review 5.  CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.

Authors:  Antoine F Carpentier; Gregor Auf; Jean-Yves Delattre
Journal:  Front Biosci       Date:  2003-01-01

6.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

7.  Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.

Authors:  H Markus Weiss; Marcel Fresneau; Thomas Moenius; Anton Stuetz; Andreas Billich
Journal:  Drug Metab Dispos       Date:  2008-06-04       Impact factor: 3.922

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 9.  Use of nanoparticles for drug delivery in glioblastoma multiforme.

Authors:  K K Jain
Journal:  Expert Rev Neurother       Date:  2007-04       Impact factor: 4.618

10.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

View more
  41 in total

1.  Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.

Authors:  Lindsay Scheetz; Padma Kadiyala; Xiaoqi Sun; Sejin Son; Alireza Hassani Najafabadi; Marisa Aikins; Pedro R Lowenstein; Anna Schwendeman; Maria G Castro; James J Moon
Journal:  Clin Cancer Res       Date:  2020-05-21       Impact factor: 12.531

2.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

Review 3.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 4.  Prospects of biological and synthetic pharmacotherapies for glioblastoma.

Authors:  David B Altshuler; Padma Kadiyala; Felipe J Nuñez; Fernando M Nuñez; Stephen Carney; Mahmoud S Alghamri; Maria B Garcia-Fabiani; Antonela S Asad; Alejandro J Nicola Candia; Marianela Candolfi; Joerg Lahann; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2020-01-20       Impact factor: 4.388

5.  Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.

Authors:  Marisa E Aikins; Cheng Xu; James J Moon
Journal:  Acc Chem Res       Date:  2020-10-05       Impact factor: 22.384

6.  The SR-B1 Receptor as a Potential Target for Treating Glioblastoma.

Authors:  Ethan Berney; Nirupama Sabnis; Marlyn Panchoo; Sangram Raut; Rob Dickerman; Andras G Lacko
Journal:  J Oncol       Date:  2019-06-03       Impact factor: 4.375

Review 7.  Targeting Glioblastoma Tumor Microenvironment.

Authors:  Megan Butler; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Nanoparticles as immunomodulators and translational agents in brain tumors.

Authors:  Adam J Grippin; Kyle A Dyson; Sadeem Qdaisat; James McGuiness; Brandon Wummer; Duane A Mitchell; Hector R Mendez-Gomez; Elias J Sayour
Journal:  J Neurooncol       Date:  2020-08-05       Impact factor: 4.130

Review 9.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

10.  Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation.

Authors:  Yufu Zhu; Jun Jia; Gang Zhao; Xuyang Huang; Lansheng Wang; Yongkang Zhang; Long Zhang; Naveena Konduru; Jun Xie; Rutong Yu; Hongmei Liu
Journal:  J Nanobiotechnology       Date:  2021-07-03       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.